User:XyZAn/sandbox/bi

Company History[edit]

Corporate Structure[edit]

Boehringer Sohn CH AG & Co. KG^{[R 1]} ^{[R 2]} ^{[N 1]}
Boehringer Ingelheim GmbH	Boehringer Ingelheim Europe GmbH	Boehringer Ingelheim International GmbH	Boehringer Ingelheim Auslandsbeteiligungs GmbH
Subsidiaries (click to reveal) Boehringer Ingelheim Pharma GmbH & Co. KG Boehringer Ingelheim Vetmedica GmbH Boehringer Ingelheim microParts GmbH Boehringer Ingelheim Biopharmaceuticals GmbH Boehringer Ingelheim Veterinary Research Centre GmbH & Co. KG	Subsidiaries (click to reveal) Boehringer Ingelheim RCV GmbH & Co. KG Boehringer Ingelheim Pharma Ges.m.b.H. Boehringer Ingelheim s.r.o. Boehringer Ingelheim Finland Ky Boehringer Ingelheim Norway KS Boehringer Ingelheim Sp.zo.o.	Subsidiaries (click to reveal) Forschungsinstitut für Molekulare Pathologie Gesellschaft mbH Boehringer Ingelheim Comm. V. Boehringer Ingelheim International Trading (Shanghai) Co. Ltd. Boehringer Ingelheim (Phil.), Inc.	Subsidiaries (click to reveal) Boehringer Ingelheim S.A. Boehringer Ingelheim Pty. Ltd. Boehringer Ingelheim do Brasil Quimica e Farmaceutica Ltda. Solana Agro Pecuaria Ltda. Boehringer Ingelheim (Canada) Ltd. Boehringer Ingelheim Ltda. Boehringer Ingelheim Shanghai Pharmaceuticals Co. Ltd. Boehringer Ingelheim (China) Investment Co. Ltd. Boehringer Ingelheim Vetmedica (China) Investment Co. Ltd. Boehringer Ingelheim Animal Health Operations (China) Co. Ltd. Boehringer Ingelheim S.A. Boehringer Ingelheim Danmark A/S Boehringer Ingelheim del Ecuador Cia. Ltda. Boehringer Ingelheim France S.A.S. Boehringer Ingelheim Ellas AE Boehringer Ingelheim India Private Ltd. PT Boehringer Ingelheim Indonesia Boehringer Ingelheim Ireland Limited Boehringer Ingelheim Italia S.p.A. Bidachem S.p.A., Fornovo S. Giovanni Nippon Boehringer Ingelheim Co. Ltd. SSP Co. Ltd. Boehringer Ingelheim Vetmedica Japan Co. Ltd. Boehringer Ingelheim Seiyaku Co. Ltd. Boehringer Ingelheim Japan, Inc. Boehringer Ingelheim Promeco S.A. de C.V., Boehringer Ingelheim Vetmedica, S.A. de C.V. Boehringer Ingelheim B.V. Boehringer Ingelheim Animal Health Operations B.V. Boehringer Ingelheim (N.Z.) Ltd. Boehringer Ingelheim Lda. Unilfarma Lda. Boehringer Ingelheim Singapore Pte. Ltd. Boehringer Ingelheim (Pty.) Ltd. Ingelheim Pharmaceuticals (Pty.) Ltd. Boehringer Ingelheim Korea Ltd. Boehringer Ingelheim España S.A. Boehringer Ingelheim S.A. Europharma S.A. Laboratorios Fher S.A. Boehringer Ingelheim AB Boehringer Ingelheim (Schweiz) GmbH Pharmaton S.A. Boehringer Ingelheim Taiwan Ltd. Boehringer Ingelheim (Thai) Ltd., Boehringer Ingelheim Ilac Ticaret A.S. Boehringer Ingelheim Ltd. Boehringer Ingelheim Corp. Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim USA Corporation Roxane Laboratories, Inc., Boehringer Ingelheim Vetmedica, Inc. Boehringer Ingelheim Roxane, Inc. Boehringer Ingelheim Fremont, Inc. Boehringer Ingelheim C.A.
(click to reveal all notes and references) Notes: ^ Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG manages to companies real-estate activities References: ^ https://www.boehringer-ingelheim.com/sites/default/files/APC/Boehringer_Ingelheim_consolidated_companies_2015.pdf ^ "C.H. Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG Firmendatenbank von Hoppenstedt". `{{cite web}}`: C1 control character in `\|title=` at position 58 (help)

Timeline[edit]

1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on 1 August.^{[citation needed]}
1886: The factory commences production of tartaric acid for use in the food industry (e.g. in baking powder and carbonated beverages).
1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer.^{[citation needed]}
1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale.
1895: Lactic acid is produced on an industrial scale, and is successful commercially.
1917: Professor Heinrich Wieland, chemist, future Nobel Prize winner and cousin of Albert Boehringer, sets up the company’s research department.
1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart.^{[citation needed]}
1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people.
1954: The company hires former Nazi Fritz Fischer after he is released from jail. Fischer was convicted of war crimes and crimes against humanity at the Nuremberg Trials.
1955: The Animal Health division is established as the company acquires Pfizer’s veterinary programme.
1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company’s North American research centre.
1985: The Institute for Molecular Pathology (IMP) is established in Vienna; it opens in 1988.
1986: The biotechnological centre in Biberach begins production of biopharmaceuticals from cell cultures.^{[citation needed]}
1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.
2006: Boehringer sold its natural healthcare company and business Pharmaton SA to IdeaSphere^[1]
2008: Boehringer acquired Actimis Pharmaceuticals for $515 million^[2]
2010: The company celebrates its 125th anniversary.
2011: Evonik Industries aquires Boehringers Resomer business.^[3]
2012: Boehringer acquired the global rights to Funxional Therapeutics’ phase 2 compound FX125L and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases.^[4]
2015: In July 2015, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones.^[5]^[6] On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer.^[7] Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.^[8]
2016: In June 2016, the company announced it had struck an asset-swap deal with Sanofi, Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the Merial animal health division (valuing it at €11.4 billion). The deal could mean that Boehringer is now one of the animal healthcare global leaders.^[9]

Collaborative research[edit]

Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.^[10]^[11] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.^[12]

^ "Boehringer Ingelheim and IdeaSphere Announce Acquisition Deal".
^ "Actimis Pharmaceuticals - CrunchBase".
^ http://www.aerosil.com/_layouts/Websites/Internet/NewsAttachmentHandlerSec.ashx?fileid=8900&newsid=18069&NewsSecToken=tBk8RyOHzOU4fQJZVr3IJzr1yUsrn9etSREq04TphLlYkC0lLfd%2Fc8wrhjDLVpTd
^ "Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional's FX125L and the somatotaxin portfolio to treat inflammation - European Pharmaceutical Review". 23 July 2012.
^ Fourcade, Marthe (28 July 2015). "Hikma to Buy Boehringer Ingelheim's Roxane for $2.65 Billion". Bloomberg.
^ "Hikma Buys Roxane for $2.65B, Expanding U.S. Generics Presence - GEN News Highlights - GEN".
^ "Boehringer Licenses Hanmi Lung Cancer Drug for Up-to $730M+ - GEN News Highlights - GEN".
^ "Boehringer dumps its Alzheimer's BACE pact with Vitae - FierceBiotech".
^ "Aiming for top dog status, Sanofi and Boehringer swap animal and consumer health units - FiercePharma".
^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
^ "InnoMed PredTox". Genedata. InnoMed PredTox Members. Retrieved 28 November 2014. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Innovative Medicines Initiative. "IMI Call Topics 2008" (PDF). EUROSFAIRE. France: Ministry of Higher Education and Research. Retrieved 2008-08-25. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[3] Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG manages to companies real-estate activities

[1] ttps://www.boehringer-ingelheim.com/sites/default/files/APC/Boehringer_Ingelheim_consolidated_companies_2015.pdf

[2] "C.H. Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG Firmendatenbank von Hoppenstedt". {{cite web}}: C1 control character in |title= at position 58 (help)

[4] "Boehringer Ingelheim and IdeaSphere Announce Acquisition Deal".

[5] "Actimis Pharmaceuticals - CrunchBase".

[6] ttp://www.aerosil.com/_layouts/Websites/Internet/NewsAttachmentHandlerSec.ashx?fileid=8900&newsid=18069&NewsSecToken=tBk8RyOHzOU4fQJZVr3IJzr1yUsrn9etSREq04TphLlYkC0lLfd%2Fc8wrhjDLVpTd

[7] "Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional's FX125L and the somatotaxin portfolio to treat inflammation - European Pharmaceutical Review". 23 July 2012.

[8] Fourcade, Marthe (28 July 2015). "Hikma to Buy Boehringer Ingelheim's Roxane for $2.65 Billion". Bloomberg.

[9] "Hikma Buys Roxane for $2.65B, Expanding U.S. Generics Presence - GEN News Highlights - GEN".

[10] "Boehringer Licenses Hanmi Lung Cancer Drug for Up-to $730M+ - GEN News Highlights - GEN".

[11] "Boehringer dumps its Alzheimer's BACE pact with Vitae - FierceBiotech".

[12] "Aiming for top dog status, Sanofi and Boehringer swap animal and consumer health units - FiercePharma".

[13] Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.

[InnoMed_PredTox_official_project_website-14] "InnoMed PredTox". Genedata. InnoMed PredTox Members. Retrieved 28 November 2014. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[IMI_Call_Topics_2008-15] Innovative Medicines Initiative. "IMI Call Topics 2008" (PDF). EUROSFAIRE. France: Ministry of Higher Education and Research. Retrieved 2008-08-25. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[R 1]

[R 2]

[N 1]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]